Top in endocrinology: Daily oral semaglutide for weight loss; intuitive eating
Click Here to Manage Email Alerts
Results from the OASIS 4 trial revealed that people with overweight or obesity assigned to once-daily oral semaglutide had a higher likelihood of significant weight loss compared with those receiving placebo plus lifestyle intervention.
“The safety profile was consistent with the known safety profile for GLP-1 receptor agonists,” W. Timothy Garvey, MD, FACE, MABOM, endocrinologist and professor at the University of Alabama at Birmingham and principal investigator of the UAB Diabetes Research Center, said during a presentation at ObesityWeek. “Oral 25 mg may represent an efficacious option for treatment of overweight and obesity, particularly in patients who prefer oral administration.”
It was the top story in endocrinology last week.
In another top story, experts discussed how intuitive eating, a philosophy to help foster a healthy relationship with food, can help patients with diabetes manage their sugar levels.
Read these and more top stories in endocrinology below:
Daily oral semaglutide confers weight loss vs. placebo; similar vs. weekly injectables
Once-daily oral semaglutide conferred more weight loss vs. placebo plus lifestyle intervention and was similar vs. larger oral GLP-1 receptor agonist doses and weekly injectables for efficacy and safety, a speaker reported at ObesityWeek. Read more.
Q&A: Intuitive eating can help people with diabetes improve their relationship with food
Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Bonnie R. Giller, MS, RDN, CDN, CDCES, registered dietitian nutritionist and certified intuitive eating counselor, about the concept of intuitive eating and how patients with diabetes can embrace this approach to help manage their blood sugar levels. Read more.
Income, insurance status contributes to rationing prescription drugs due to cost
Due to structural barriers such as low income and inadequate insurance coverage, Black and Hispanic adults were more likely to ration prescription drugs to save money, researchers reported. Read more.
Diabetes inequities persist worldwide, especially for low-, middle-income countries
From 1990 to 2022, diabetes prevalence rose greatly, but for the most part, treatment did not increase at all or sufficiently, especially in low- and middle-income countries, researchers reported in The Lancet. Read more.
High- vs. moderate-intensity exercise reduces ghrelin levels regardless of sex
Regardless of sex, high- vs. moderate-intensity exercise may better reduce ghrelin levels, but its effect on hunger perceptions may differ between men and women, according to results published in the Journal of the Endocrine Society. Read more.